In Brief: Colgate-Palmolive

Colgate-Palmolive: Sorriso toothpaste, debuting in Brazil with a $20 mil. ad spend for the remainder of 1997, replaces Colgate's recently acquired Kolynos toothpaste brand, the company said. The launch follows a ruling by the Brazilian anti-trust agency Cade that Colgate cannot sell Kolynos under that brand name for a four-year period ("The Rose Sheet" March 24, In Brief). The company has no plans to distribute Sorriso ("smile" in Portuguese) in other Latin American or European countries where Kolynos is marketed. Kolynos dental flosses and toothbrushes will continue to be available in the country...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from HBW Insight

Green Regulation Is ‘A Baseline Not A Burden’ – Behind Opella’s B Corp Journey

 
• By 

“For us, regulation is the floor, not the ceiling,” Opella's chief sustainability officer Marissa Saretsky tells HBW Insight as the firm gains B Corp Certification. Other topics covered in this exclusive interview include Opella's position on the revised Urban Wastewater Treatment Directive.

FDA Warns Whoop BPI App Is Unauthorized Device; Firm Says Wearable Is A Wellness Tool

 

Recent FDA warning letter claims Boston firm specializing in wearable technology marketed a blood pressure device without agency approval, but the company rejects the assertion and says the agency is out of step with federal regulations.

Questions For FDA On OTC Switches, Alternative Tests And Budget Cuts At OMUFA Hearing

 

Texas Democrat Lizzie Fletcher didn’t pose questions for witnesses at House Health Subcommittee hearing but used her floor time to question whether Congress will keep federal agencies afloat. “I have real concerns that even if we reauthorize these programs, we won't have the funding or the staff to